Amplicon structure creates collateral therapeutic vulnerability in cancer
Y. Bei, L. Brame, M. Kirchner, R. Fritsche, S. Kunz, A. Bhattacharya, J. Koeppke, J. Proba, N. Wittstruck, O. Sidorova, R. Chamorro, H. Dorado Garcia, L. Brueckner, R. Xu, M. Giurgiu, , A. Henssen
The paper identifies DDX1 as a passenger gene co-amplified with MYCN in cancer, showing that its aberrant expression creates a therapeutic vulnerability through mTORC1 dependency.
bioRxiv · Sep 8, 2022 · PreprintCancer Biology